Research Topics
Genomes and GenesSpecies | Hirofumi MukaiSummaryAffiliation: National Cancer Center Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Targeted therapy in breast cancer: current status and future directionsHirofumi Mukai
Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
Jpn J Clin Oncol 40:711-6. 2010..Oncologists will be required to master appropriate initial therapy to treat them; on the other hand, oncologists need to cooperate with specialists in other fields more than they used to...- Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is neededHirofumi Mukai
Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
Breast Cancer Res Treat 113:123-8. 2009..Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of definitions... - Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC)Hirofumi Mukai
Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
Jpn J Clin Oncol 40:811-4. 2010..A threshold hazard ratio of 1.333 will be used to determine whether overall survival in the TS-1 group is equivalent (not inferior) to that in the taxane group. The target number of registered patients is 600... - An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patientsHirofumi Mukai
Division of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Jpn J Clin Oncol 36:808-10. 2006..It is necessary to evaluate many modes of complementary and alternative medicines, including the Agaricus blazei extract, in rigorous, scientifically designed and peer-reviewed clinical trials... - Treatment strategy for HER2-positive breast cancerHirofumi Mukai
Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, Japan
Int J Clin Oncol 15:335-40. 2010..Biomarkers are being aggressively searched for concerning individual drugs under development. A position of the "proper drug for the proper patient" will be more firmly established... - Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancerHirofumi Mukai
Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
Am J Clin Oncol 33:32-5. 2010..Evaluation of the safety and efficacy of docetaxel and cisplatin in the treatment of unknown primary cancer... - Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neckMakoto Tahara
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
Cancer Sci 102:419-24. 2011..Administration of S-1 as a suspension or by whole capsule can be considered therapeutically interchangeable. Although these data are preliminary, activity was highly promising, and this approach warrants further investigation... - Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumorsHironobu Minami
Oncology Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
Cancer Sci 99:1492-8. 2008..In conclusion, sorafenib 400 mg bid was well tolerated in Japanese patients with advanced refractory solid tumors. The recommended dose for future clinical trials is 400 mg bid... - Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patientsToru Mukohara
National Cancer Center Hospital East, Oncology Hematology, Kashiwa, Japan
Cancer Sci 101:963-8. 2010..Axitinib 5 mg twice-daily is the recommended starting dose for Japanese patients. This trial is registered with ClinicalTrials.gov, identifier NCT00447005... - Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancerMikiya Ishihara
Division of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Int J Clin Oncol 14:431-5. 2009..Safety information on adjuvant trastuzumab use in Japanese patients, especially cardiac toxicity data, is needed... - Elderly breast cancer therapy: a Japanese experienceYoichi Naito
Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Jpn J Clin Oncol 40:717-21. 2010..However, there seems to be a substantial undertreatment in the elderly... - Review of primary unknown cancer: cases referred to the National Cancer Center Hospital EastNobuaki Matsubara
Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Int J Clin Oncol 15:578-82. 2010..We analyzed cases that were referred to the National Cancer Center Hospital East with preliminary diagnosed PUC to evaluate the natural history and clinical features... - [Clinical diagnosis of primary unknown cancer-the present situation and problems]Hirofumi Mukai
Division of Chemotherapy, National Cancer Center Hospital East, Japan
Gan To Kagaku Ryoho 36:915-7. 2009..There is not enough evidence on the utility of FDG-PTT or FDG-PET/CT for patients with PUC. Diagnosis of PUC should be made within one month from a patient's first visit to a hospital... - Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxelHirofumi Mukai
Department of Medical Oncology, National Cancer Center Hospital, 5 5 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
Int J Clin Oncol 8:23-5. 2003..We examined the feasibility of using a combination of docetaxel and cisplatin for the treatment of unknown primary carcinoma in order to prepare a larger scale prospective study... - Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancerNobuaki Matsubara
Department of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
Oncology 81:345-52. 2011..Ki-67 overexpression has been reported to be related to a poor prognosis for early stage breast cancer. We analyzed whether Ki-67 has a prognostic impact on risk subgroups based on the recommendations at St. Gallen in 2007... - Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumorsKenji Kawada
Department of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Japan
Jpn J Clin Oncol 37:44-8. 2007.... - E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cellsChisako Yamauchi
Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Int J Cancer 128:2125-37. 2011.... - [Management of toxicity associated with chemotherapy for breast cancer]Toru Mukohara
Division of Hematology/Oncology, National Cancer Center Hospital East
Nippon Rinsho 65:516-22. 2007 - The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephoneToshiro Mizuno
Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Support Care Cancer 15:287-91. 2007..The purpose of this retrospective study is to evaluate the feasibility of the risk assessment over the telephone in the outpatient management of low-risk febrile patients with neutropenia... - Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)Masafumi Kurosumi
Department of Pathology, Saitama Cancer Center, Saitama, Japan
Breast Cancer 15:5-7. 2008 - Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patientsMiki Nakajima
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma machi, Kanazawa 920 1192, Japan
Pharmacogenet Genomics 17:431-45. 2007..To evaluate the effects of genetic polymorphisms of drug metabolizing enzymes on the pharmacokinetics of cyclophosphamide and its active metabolite, 4-hydroxycyclophosphamide, and on the pharmacodynamics... - [Treatment guidelines for systemic adjuvant therapy of breast cancer]Toru Watanabe
Hamamatsu Oncology Center Clinic
Nippon Rinsho 64:419-23. 2006..Guidelines that have authority in the adjuvant treatment of breast cancer are the NIH and NCCN guidelines, those developed in St. Gallen and those by Japan Breast Cancer Society... - [Genetic testing for effective Herceptin therapy]Toru Watanabe
Department of Medical Oncology, National Cancer Center Hospital
Nippon Rinsho 60:603-11. 2002..The experience gained in the testing of Herceptin has provided important lessons for the future testing of molecularly targeted compounds...